1990至2017年全球29个癌症组的发病率、死亡率、寿命损失年、伤残损失健康生命年和伤残调整生命年:全球疾病负担研究的系统分析
该研究基于全球疾病负担(GBD)研究方法,描述了1990至2017年195个国家29个癌症组的疾病负担。癌症DALYs主要来自寿命损失年(97%),仅3%来自伤残损失健康生命年。不同SDI五分位之间癌症发病风险差异显著,低SDI组为1/7,高SDI组为1/2。
要点
- 癌症DALYs的97%来自寿命损失年,仅3%来自伤残损失健康生命年。
- 男性最常见新发癌症为NMSC、气管支气管肺癌和前列腺癌;女性为NMSC、乳腺癌和结直肠癌。
核心结论
- GBD研究显示各国癌症负担流行病学特征存在很大异质性,反映了危险因素暴露、经济环境、生活方式及医疗和筛查可及性的差异。
- GBD研究可用于政策制定者和其他利益相关方制定和改进国家和地方癌症控制规划,以实现全球目标并改善癌症诊疗公平性。
研究设计与样本
- 采用GBD研究估算方法,描述1990至2017年195个国家29个癌症组的癌症发病率、死亡率、伤残损失健康生命年、寿命损失年和伤残调整生命年(DALYs)。
- 结果按国家水平及社会人口指数(SDI)呈现,SDI是收入、教育程度和总和生育率的综合指标。
- 分析了流行病学转变与人口学转变对癌症发病率的影响。
主要发现
- 癌症DALYs的97%来自寿命损失年,仅3%来自伤残损失健康生命年。
- 男女两性中,低SDI五分位组癌症发病风险最低(1/7),高SDI五分位组最高(1/2)。
临床怎么用
- 可利用GBD研究提供的国家癌症流行病学特征制定和优化国家及地方癌症控制规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. OBJECTIVE: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. EVIDENCE REVIEW: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. FINDINGS: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs). CONCLUSIONS AND RELEVANCE: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.
引用
- Fitzmaurice C, Abate D, Abbasi N, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019. PMID: 31560378. doi:10.1001/jamaoncol.2019.2996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。